Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
New expert interviews, 29th June, 2015, Amsterdam, The Netherlands
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
Klaus Brasso, Frederik B. Thomsen, Andres J. Schrader, Sebastian C. Schmid, David Lorente, Margitta Retz, Axel S. Merseburger, Christoph A. von Klot, Martin Boegemann, Johann de Bono
European Urology 2015 Aug;68(2):317-24
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL)
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al.Lancet Oncol. 2015 May;16(5):509-21
The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Ottavio De Cobelli, Franco Nolè
European Journal of Cancer, Volume 51, Issue 14, September 2015, Pages 1970 - 1977
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, et al.BJU International 2015 Jan 30. [Epub ahead of print]
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
Shigeta K, Kosaka T, Yazawa S, Yasumizu Y, Mizuno R, Nagata H, et al.Int J Clin Oncol. 2015 Jun;20(3):605-12.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Sep 20153Sep 20155Alicante, SpainContact: Congress Consultants B.V. Tel.: +31 26 389 1751 Fax: +31 26 389 1752 E-mail: firstname.lastname@example.org
- Sep 201523Sep 201526Contact: DGU Tel.: +49 211 516 0960 Fax: +49 211 516 0960 E-mail: email@example.com